Navigation Links
ConfometRx and UCB Announce New R&D Partnership

PALO ALTO, Calif., Feb. 21, 2013 /PRNewswire-USNewswire/ -- ConfometRx announced today that it has sealed a research agreement with UCB to enable the discovery of novel medicines addressing unmet medical need in Neuroscience. Under this two-year multi-target agreement UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs. GPCRs are the largest family of signaling proteins in the human genome. They are involved in virtually all physiological processes and represent the single largest target class for medicines on the market.  The terms of the agreement, whose details are not disclosed, include an up-front payment, research funding and success-based milestones.


Tong Sun Kobilka , CEO of ConfometRx, said: "We are delighted to be working with UCB's world-class Central Nervous System research group to enhance their drug development activities. With over 20 years of experience working in the coupled receptor field and our unique technological approach, we believe that we can bring significant value to UCB's novel drug development process. We look forward to working closely with UCB's R&D teams."  

Ismail Kola, Executive Vice President and President, NewMedicines at UCB said, "GPCR crystallization remains a challenge and requires state-of-the-art technologies as well as expertise. Professor Brian Kobilka is the first to have succeeded in crystallizing a GPCR target in the active state and was awarded the chemistry Nobel prize for his work in the field of GPCR structural biology. We look forward to working with ConfometRx as part of our continued strategy to innovate in drug discovery, transforming knowledge and insight into health-changing invention. We strive to fulfill our mission of discovering new medicines that aim to improve the lives of people living with severe diseases. The collaboration with ConfometRx is another example of UCB's strategies at work where we are continuing building supernetworks of innovation that are aimed at building superior and sustainable value for patients."

About ConfometRx
ConfometRx, a leader in G protein coupled receptor (GPCR) structural characterization and analysis, has exclusive rights to the patented T4-lysozyme (T4-L) protein fusion stabilization technology used to solve at least thirteen novel GPCR structures.  This pioneering protein fusion technology was developed by Stanford Professor and ConfometRx co-Founder, Dr. Brian Kobilka , and Stanford University has been awarded six separate patents on this fundamental technology with other patents still pending both in the U.S. and abroad.

If you have any questions or would like to learn more about ConfometRx's proprietary technology or to discuss a possible partnering arrangement in the United States or abroad, please contact Dickstein Shapiro LLP, Attn: Deborah Fishman , 1841 Page Mill Road, Suite 150, Palo Alto, CA 94304, phone: (650) 690-9500, fax: (650) 690-9501, e-mail:

SOURCE ConfometRx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
3. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... Lizzie’s Lice Pickers ... company is offering customers 10% off of their purchase of lice treatment product. In ... full price. According to a company spokesperson. “Finding lice is a sure way to ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... ... 27, 2015 , ... The men and women on this ... in the country. They have overseen financial turnarounds, shown commitment to their community ... industry as a whole through their advocacy and professional efforts. , Becker's Hospital ...
(Date:11/26/2015)... ... ... Inevitably when people think Thanksgiving, they also think Holiday sales and start ... and Cyber Monday massage chair sales to receive the best pricing on ... find the best massage chair deals, they can see all of the coupons in ...
(Date:11/26/2015)... ... 26, 2015 , ... PRMA Plastic Surgery is updating their record books yet ... 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, ... lives and it’s an honor to have served all of these women.” , PRMA ...
Breaking Medicine News(10 mins):